Pluristem Therapeutics: Surges on positive leg pain treatment data

Pluri

12/06/2018 11:21

** Drug developer's shares  PSTI.O  surges 27.9 pct to $1.77
 premarket - second most actively-traded Nasdaq-listed stock 
    ** Set to open at near 7-month high, if session gains hold
    ** Reports positive mid-stage data testing its PLX-PAD cell
therapy for treatment of intermittent claudication, or pain in
legs caused by too little blood flow  urn:newsml:reuters.com:*:nGNX7kHN1X
    ** Treatment showed statistically significant improvement in
maximum distance patients could walk, when compared to placebo
-co 
    ** Study results validate design of Pluristem's ongoing
phase III study in CLI, more severe stage of peripheral arterial
disease - Pluristem 
    ** Stock had risen 6.1 pct in the past 12 months 

 (Reporting by Manas Mishra in Bengaluru)
 ((Reuters Messaging:
manas.mishra.thomsonreuters.com@reuters.net))